| Not Yet Recruiting | BV-CHP Real-life and Biological Evidences in Patients With sALCL Anaplastic Large Cell Lymphoma | — | 2026-05-01 |
| Not Yet Recruiting | Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymph Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B | N/A | 2026-05-01 |
| Not Yet Recruiting | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL) | — | 2026-05-01 |
| Not Yet Recruiting | Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy Mantle Cell Lymphoma | Phase 2 | 2026-04-15 |
| Not Yet Recruiting | PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma Hodgkin Lymphoma | Phase 3 | 2026-03-01 |
| Not Yet Recruiting | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma Mantle Cell Lymphoma | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | Long-term Assessment of Chlormethine Gel in Mycosis Fungoides Cutaneous T-Cell Lymphoma/Mycosis Fungoides | — | 2025-09-01 |
| Recruiting | Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | — | 2025-05-05 |
| Recruiting | A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-ce Diffuse Large B Cell Non-Hodgkin Lymphoma | Phase 2 | 2025-04-09 |
| Recruiting | Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | — | 2025-02-27 |
| Recruiting | Study on Plasmablastic Lymphoma Patients Plasmablastic Lymphoma | — | 2025-02-14 |
| Active Not Recruiting | Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's M Waldenström's Macroglobulinemia (WM) | — | 2024-12-13 |
| Active Not Recruiting | PTLD: Multicentric Retrospective Study PTLD | — | 2024-10-30 |
| Recruiting | Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients Follicular Lymphoma | Phase 2 | 2024-10-23 |
| Recruiting | Primary Cardiac Lymphoma: Italian Multicenter Experience Primary Cardiac Lymphoma | — | 2024-10-02 |
| Completed | Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome | — | 2024-06-06 |
| Recruiting | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standar Hodgkin Lymphoma | Phase 2 | 2024-05-23 |
| Recruiting | Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immun Follicular Lymphoma | — | 2024-05-07 |
| Recruiting | SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR Non-hodgkin Lymphoma,B Cell | — | 2024-04-18 |
| Recruiting | Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | N/A | 2024-02-26 |
| Withdrawn | R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2 | 2024-01-01 |
| Recruiting | A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non- Non-Hodgkin Lymphoma, B-cell | — | 2023-12-27 |
| Recruiting | Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: Follicular Lymphoma | Phase 3 | 2023-12-14 |
| Recruiting | Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Follicular Lymphoma | — | 2023-09-19 |
| Recruiting | Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients Relapsed or Refractory Hodgkin's Lymphoma | Phase 1 / Phase 2 | 2023-02-27 |
| Active Not Recruiting | Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Stud Mantle Cell Lymphoma | — | 2023-02-08 |
| Recruiting | Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma Low Grade Non-Hodgkin's Lymphoma, Adult | — | 2022-12-07 |
| Recruiting | Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. Plasmablastic Lymphoma | Phase 2 | 2022-07-11 |
| Recruiting | Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intol Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | 2022-03-21 |
| Active Not Recruiting | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Follicular Lymphoma | Phase 3 | 2021-12-01 |
| Recruiting | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy Diffuse Large B-Cell Lymphoma, Elderly Patients | Phase 3 | 2021-03-23 |
| Completed | The Role of 18F-FDG-PET for Staging and Prognostication Mantle Cell Lymphoma | — | 2020-10-30 |
| Terminated | Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Phase 2 | 2020-09-03 |
| Terminated | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma Diffuse Large B-cell Lymphoma | Phase 2 | 2020-08-18 |
| Completed | Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial Hodgkin Lymphoma | — | 2020-04-08 |
| Terminated | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma Follicular Lymphoma | Phase 2 | 2019-10-18 |
| Completed | Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study Primary Mediastinal Large B-cell Lymphoma (PMBCL) | — | 2019-10-02 |
| Unknown | Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Mantle Cell Lymphoma | Phase 2 | 2019-09-30 |
| Active Not Recruiting | Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance DLBCL | Phase 2 | 2019-07-02 |
| Terminated | Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lympho T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory | Phase 2 | 2018-09-25 |
| Completed | Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL Lymphoma, Mantle-Cell | Phase 2 | 2018-09-03 |
| Completed | Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in Waldenstrom Macroglobulinemia | — | 2018-08-28 |
| Unknown | Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis Classical Hodgkin Lymphoma | — | 2018-08-10 |
| Completed | Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas Aggressive Non-Hodgkin Lymphoma | Phase 2 | 2017-09-12 |
| Completed | FIL Study on ABVD DD-DI as Upfront Therapy in HL. Hodgkin Lymphoma | Phase 3 | 2017-08-01 |
| Completed | A Phase II Study of the FIL on Elderly Frail Patients With DLBCL Diffuse Large B-cells Non-Hodgkin Lymphoma | Phase 2 | 2016-09-01 |
| Terminated | Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patien Lymphoma, B-Cell | Phase 2 | 2016-09-01 |
| Completed | Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression Follicular Lymphoma | — | 2016-05-01 |
| Completed | Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infe Indolent B-cell Lymphoma, Hepatitis C | Phase 2 | 2016-03-01 |
| Terminated | Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting Lymphatic Diseases | Phase 2 | 2015-12-23 |
| Completed | Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Pa Lymphatic Diseases | Phase 2 | 2015-09-21 |
| Terminated | GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lym CD20 Positive Diffuse Large B-cell Lymphoma, Elderly Unfit Patients | Phase 2 | 2015-08-25 |
| Completed | BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV Relapsed/Refractory Hodgkin's Lymphoma | Phase 2 | 2014-12-01 |
| Terminated | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients Diffuse, Large B-Cell, Lymphoma | Phase 2 | 2014-11-05 |
| Completed | "MIRO" Molecularly Oriented Immuno-radio-therapy Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade 3A | Phase 2 | 2014-10-01 |
| Active Not Recruiting | Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas Peripheral T-cell Lymphomas (PTCL), PTCL-NOS, Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 1 / Phase 2 | 2014-09-01 |
| Completed | Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's Waldenstrom's Macroglobulinemia | Phase 2 | 2014-06-01 |
| Active Not Recruiting | Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Pa Lymphoma, Follicular | Phase 3 | 2014-05-01 |
| Completed | Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell Lymphoma, Large B-Cell, Diffuse Large B-Cell | — | 2014-02-12 |
| Unknown | Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Ther Non Hodgkin Lymphoma | Phase 2 | 2014-02-01 |
| Completed | A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL Primary Mediastinal Large B Cell Lymphoma | Phase 2 | 2013-10-01 |
| Unknown | Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM Lymphoma, Large B-Cell, Diffuse | — | 2013-09-01 |
| Completed | Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disea Hodgkin Lymphoma | Phase 2 | 2013-02-04 |
| Completed | Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2 / Phase 3 | 2013-02-04 |
| Completed | Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients Peripheral T-cell Lymphoma | Phase 2 | 2013-01-01 |
| Completed | Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL Mantle Cell Lymphoma | Phase 2 | 2012-07-31 |
| Completed | Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma Follicular Non-Hodgkin's Lymphoma | Phase 3 | 2012-07-01 |
| Completed | Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma | Phase 2 | 2012-03-20 |
| Completed | Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma Hodgkin Lymphoma | Phase 2 | 2012-02-01 |
| Completed | R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients Diffuse Large B Cell Lymphoma | Phase 2 | 2012-01-01 |
| Unknown | A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) Relapsed Follicular Lymphoma | Phase 3 | 2012-01-01 |
| Unknown | Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase Diffuse Large B-cell Lymphoma | Phase 2 | 2011-11-01 |
| Completed | Indolent Non Follicular Lymphomas Prognostic Project Indolent B-Cell Lymphomas | — | 2011-09-01 |
| Completed | Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for AS Diffuse Large B-cell Lymphoma | Phase 2 | 2011-02-01 |
| Completed | A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma Indolent Non-follicular, Non-Hodgkin's Lymphoma | Phase 2 | 2011-01-01 |
| Completed | A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) Hodgkin Lymphoma | Phase 2 | 2010-11-01 |
| Unknown | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and AS MANTLE CELL LYMPHOMA | Phase 3 | 2010-05-01 |
| Unknown | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Diffuse Large B-Cell Lymphoma | Phase 2 | 2010-05-01 |
| Completed | Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDC Hodgkin's Lymphoma | — | 2010-05-01 |
| Completed | Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymp Follicular Lymphoma | Phase 2 | 2009-06-01 |
| Terminated | Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory Hodgkin's Lymphoma | — | 2009-05-01 |
| Completed | Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen B-Cell Lymphomas | — | 2009-05-01 |
| Unknown | Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensi Lymphoblastic Lymphoma | — | 2009-04-01 |
| Completed | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Hodgkin's Lymphoma | Phase 2 / Phase 3 | 2008-09-01 |
| Completed | Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Ce MANTLE CELL LYMPHOMA | Phase 2 | 2008-07-01 |
| Unknown | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Eld Non Hodgkin Lymphoma, Follicular Lymphoma | Phase 2 | 2007-10-01 |
| Unknown | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Aut Diffuse Large B-Cell Lymphoma, IPI≥2 | Phase 3 | 2006-01-01 |
| Unknown | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular L Follicular Lymphoma | Phase 3 | 2005-12-01 |
| Completed | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL Elderly Patients (>65 Years), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 3 | 2003-01-01 |